This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 7.25% and 8.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
by Zacks Equity Research
CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline
by Zacks Equity Research
Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
by Zacks Equity Research
UHS' first-quarter earnings are likely to have benefited from growing admissions and patient days.
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
by Zacks Equity Research
HCA's first-quarter earnings are likely to have benefited from growing admissions.
Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch
by Zacks Equity Research
MOH's first-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 11.76% and 12.33%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Molina Healthcare to Report Q4 Earnings: What Do the Estimates Say?
by Zacks Equity Research
MOH's fourth-quarter earnings are likely to have benefited from growing premiums, partially offset by higher expenses.
Can Centene's Q4 Earnings Navigate Through Rising Medical Costs?
by Zacks Equity Research
CNC's fourth-quarter earnings are likely to have benefited from growing Commercial business.
Rising Medical Costs to Affect Cigna Q4 Earnings? Check Estimates Here
by Zacks Equity Research
CI's fourth-quarter results are likely to have benefited from growing premiums and pharmacy revenues.
CRISPR Therapeutics (CRSP) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down -9.11% in 4 Weeks, Here's Why Tarsus Pharmaceuticals (TARS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Strength Seen in Novavax (NVAX): Can Its 10.9% Jump Turn into More Strength?
by Zacks Equity Research
Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Zacks Analyst Blog Highlights ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex
by Zacks Equity Research
ADMA Biologics, Tarsus Pharmaceuticals, Stoke Therapeutics, Inc. and ChromaDex are part of the Zacks top Analyst Blog.
4 Drug, Biotech Stocks Rising More Than 50% in 2024 With Room to Grow
by Zacks Equity Research
Here, we discuss four biotech stocks, ADMA, TARS, STOK and CDXC, which have returned more than 50% year to date and have room for more growth in 2025.
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 32.22% and 11.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
2seventy bio, Inc. (TSVT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -28.57% and 33.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Amicus Therapeutics (FOLD) Stock Jumps 14.0%: Will It Continue to Soar?
by Zacks Equity Research
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 10.20% and 30.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?